Home
Home

Arena

An Obesity Drugmaker's Critical Coming Weeks

An Obesity Drugmaker's Critical Coming Weeks
Motley Fool

It's Now Time For Vivus Investors To Watch Arena Numbers

It's Now Time For Vivus Investors To Watch Arena Numbers
Seeking Alpha

Arena's Marketing Partner Eisai Pharma Seeks Expedited Final Ruling From DEA To Begin Belviq Sales

Arena's Marketing Partner Eisai Pharma Seeks Expedited Final Ruling From DEA To Begin Belviq Sales
Seeking Alpha

The Looming EU Approval Makes Arena Pharmaceuticals Significantly Undervalued

The Looming EU Approval Makes Arena Pharmaceuticals Significantly Undervalued
Motley Fool

This Week in Biotech

This Week in Biotech
Motley Fool

Good News for Vivus and Arena

Good News for Vivus and Arena
Motley Fool

Science Arena Investors Need to Know

Science Arena Investors Need to Know
Motley Fool

Arena And Vivus Set To Dominate The Obesity Drug Market

Arena And Vivus Set To Dominate The Obesity Drug Market
Seeking Alpha

3 Drug Companies That Want to Lose

3 Drug Companies That Want to Lose
Motley Fool

Arena Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Arena Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Seeking Alpha